Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 8/20 | 0.46 |
| ▸ | CA1 | P00915 | 8/20 | 0.46 |
| ▸ | CA2 | P00918 | 8/20 | 0.46 |
| ▸ | CA9 | Q16790 | 8/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.38 |
| ▸ | PSMD11 | O00231 | 1/20 | 0.37 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.37 |
| ▸ | GIGYF2 | Q6Y7W6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL79858 | 0.97 | CA12 (0.44) | CA12CA1CA2CA9ITGB1 | |
| SCHEMBL80511 | 0.85 | CA12 (0.45) | CA12CA1CA2CA9ITGB1 | |
| SCHEMBL79845 | 0.77 | NAMPT (0.36) | — | |
| SCHEMBL79217 | 0.74 | CYP1A2 (0.47) | — | |
| SCHEMBL87586 | 0.74 | CYP1A2 (0.47) | — | |
| SCHEMBL30338340 | 0.74 | CYP1A2 (0.47) | — | |
| SCHEMBL30712995 | 0.73 | TUBB4A (0.41) | — | |
| SCHEMBL806877 | 0.72 | CYP1A2 (0.41) | — | |
| SCHEMBL31578430 | 0.70 | CA12 (0.74) | CA12CA1CA2CA9ITGB1 | |
| SCHEMBL9412855 | 0.69 | CA12 (0.75) | CA12CA1CA2CA9ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129527-B2 | cancer and non-cancer diseases associated with vascular proliferation; mitoxantrone resistant, taxol resistant cancers | NEREUS PHARMACUTICALS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129527-B2 | cancer and non-cancer diseases associated with vascular proliferation; mitoxantrone resistant, taxol resistant cancers | NEREUS PHARMACUTICALS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20080221122-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THEAPEUTIC USE | BEYONDSPRING PHARMACEUTICALS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221122-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THEAPEUTIC USE | BEYONDSPRING PHARMACEUTICALS, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221122-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THEAPEUTIC USE | HPGDS, DHPS, HCCS | CA12 4187/4885CA1 4739/4885CA2 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.